The relationship between SGLT2 and systemic blood pressure regulation.

The sodium-glucose cotransporter 2 (SGLT2) is a glucose transporter that is located within the proximal tubule of the kidney's nephrons. While it is typically associated with the kidney, it was later identified in various areas of the central nervous system, including areas modulating cardiorespiratory regulation like blood pressure. In the kidney, SGLT2 functions by reabsorbing glucose from the nephron's tubule into the bloodstream. SGLT2 inhibitors are medications that hinder the function of SGLT2, thus preventing the absorption of glucose and allowing for its excretion through the urine. While SGLT2 inhibitors are not the first-line choice, they are given in conjunction with other pharmaceutical interventions to manage hyperglycemia in individuals with diabetes mellitus. SGLT2 inhibitors also have a surprising secondary effect of decreasing blood pressure independent of blood glucose levels. The implication of SGLT2 inhibitors in lowering blood pressure and its presence in the central nervous system brings to question the role of SGLT2 in the brain. Here, we evaluate and review the function of SGLT2, SGLT2 inhibitors, their role in blood pressure control, the future of SGLT2 inhibitors as antihypertensive agents, and the possible mechanisms of SGLT2 blood pressure control in the central nervous system.

Paratesticular leiomyosarcoma with metastasis to the extremities and lungs.

Paratesticular leiomyosarcoma is a rare malignant tumor deriving from the smooth muscle of structures surrounding the testes, including the epididymis or scrotum. With few cases of genitourinary soft tissue sarcomas reported in the literature, little is known about progression, management, and treatment. Herein, we report a case of metastatic paratesticular leiomyosarcoma in a 47-year-old male with no past urological history. The patient initially presented with a firm, painless right scrotal mass, and ultimately developed soft tissue and pulmonary metastases.